A new report by DART Markets forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.
This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:
- Wet age-related macular degeneration (wAMD)
- Dry AMD (dAMD)
- Diabetic retinopathy (DR)
- Other retinal diseases (grouped forecast).
The study also provides revenues and forecast of five prominent drugs to 2026:
This report discusses the competitive landscape in the retinal diseases drugs market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.
Research, data and analyses cover activities of leading companies in the retinal diseases drugs industry: - Roche
- Other manufacturers and marketers of ophthalmic pharmaceuticals
This new study also discusses leading pipeline candidates for Wet AMD, Dry AMD, and Diabetic Retinopathy, shows two interviews and predicts revenues to 2026 in 11 leading national markets.
The work analyses these national markets:
- EU5 (Italy, Spain, Germany, the UK and France)
- BRIC (Brazil, Russia, India and China)
- Rest of the World
This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:
- Emerging Markets
Our reports have been used by over 10K customers, including:
Conjunctivitis Market Research Report by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, and Viral Conjunctivitis) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Conjunctivitis Market is expected to grow from USD 2,873.90 Million in 2019 to USD 3,410.73 Million by the end of 2025...
Age Related Macular Degeneration - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape. Age...
Alpha Synuclein - Pipeline Review, H1 2020 Summary According to the recently published report ’Alpha Synuclein – Pipeline Review, H1 2020’; Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 57 molecules....
Complement C5 - Pipeline Review, H1 2020 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 34 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes....
Soluble Guanylate Cyclase - Pipeline Review, H1 2020 Summary Soluble Guanylate Cyclase (sGC or EC 184.108.40.206) – Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP....
Allergic Rhino-Conjunctivitis Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Allergic Rhino-Conjunctivitis Global Clinical Trials Review, H1, 2020" provides an overview of Allergic Rhino-Conjunctivitis Clinical trials scenario.This report provides top line data relating...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.